...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >Progress in clincal neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors.
【24h】

Progress in clincal neurosciences: Treatment of Alzheimer's disease and other dementias--review and comparison of the cholinesterase inhibitors.

机译：临床神经科学方面的进展：阿尔茨海默氏病和其他痴呆的治疗-胆碱酯酶抑制剂的审查和比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Alzheimer's disease (AD) is the most common cause of dementia in older adults. Acceptance of the cholinergic hypothesis led to a search for medications which could enhance central cholinergic activity in this condition. There are now three cholinesterase inhibitors available for the treatment of AD in Canada. OBJECTIVES: To review the currently available cholinesterase inhibitors approved for the treatment of AD in Canada and to provide guidance on who and how to treat with these agents. RESULTS: Donepezil, rivastigmine, and galantamine are approved for the treatment of AD in Canada. In clinical trails, patients with mild to moderate AD treated with these agents experienced modest improvements in cognition, function, behaviour, and/or global clinical state. The magnitude of benefits seen with each agent appeared to be similar. While to date, there is no convincing evidence that one is more efficacious or effective, they do differ in their pharmacokinetics, additional mechanisms of action, and side effect profiles. Therefore, the selection of agent will be based on considerations such as side effect profiles, ease of administration, personal familiarity/experience, and beliefs about the importance of the noted differences in their pharmacokinetics and additional mechanisms of action. CONCLUSION: We believe that these agents should be offered to all individuals with a mild to moderate dementia where Alzheimer's pathology is felt to be a contributing factor. We view all three available cholinesterase inhibitors as first-line drugs.
机译：背景：阿尔茨海默氏病（AD）是老年人痴呆症的最常见原因。胆碱能假说的接受导致寻找可以增强这种情况下中枢胆碱能活性的药物。现在，加拿大有三种胆碱酯酶抑制剂可用于治疗AD。目的：回顾加拿大目前批准的用于治疗AD的胆碱酯酶抑制剂，并就谁以及如何使用这些药物治疗提供指导。结果：多奈哌齐，卡巴拉汀和加兰他敏在加拿大被批准用于治疗AD。在临床试验中，用这些药物治疗的轻度至中度AD患者在认知，功能，行为和/或整体临床状态方面均有适度的改善。每种药物所见效益的大小似乎相似。迄今为止，尚无令人信服的证据表明一种药物更为有效或有效，但它们的药代动力学，其他作用机制和副作用情况确实存在差异。因此，药剂的选择将基于诸如副作用概况，易于给药，个人熟悉/经验以及对药代动力学中所指出的差异的重要性和其他作用机制的信念等考虑。结论：我们认为这些药物应该提供给所有轻度至中度痴呆的患者，在这些患者中，阿尔茨海默氏病被认为是一个重要因素。我们将所有三种可用的胆碱酯酶抑制剂视为一线药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号